Acute and Long-Term Management of Cannabinoid Hyperemesis Syndrome

Acute Management in the Emergency Department

• Complete cannabis cessation for at least 6 months is the foundational treatment, combined with rapid symptom control using topical 0.1 % capsaicin cream and a dopamine antagonist (haloperidol or droperidol). 1
• Topical 0.1 % capsaicin cream applied to the abdomen and epigastrium activates TRPV1 receptors and provides rapid relief of vomiting and nausea. 1, 2
• Haloperidol is the preferred dopamine antagonist for acute CH‑S episodes; studies show it is more effective than traditional anti‑emetics. 1
• Benzodiazepines such as lorazepam may be used for acute symptom control, but they are not recommended as first‑line therapy. 1
• Promethazine, olanzapine, and ondansetron have limited supporting evidence and may be trialed only after first‑line agents fail. 1, 3
• Opioids must be avoided entirely because they exacerbate nausea and carry a high addiction risk in this population. 1, 4

Long‑Term Management

• Structured cannabis‑cessation counseling is the only definitive cure and should be reinforced at every patient encounter. 1, 5
• Symptoms typically resolve after a minimum of 6 months of complete abstinence (or after a period equal to three typical vomiting cycles). 1, 6
• Amitriptyline (75–100 mg at bedtime) is the mainstay of long‑term pharmacotherapy for CH‑S. 1, 4
• Amitriptyline should be initiated at 25 mg and titrated weekly in 25‑mg increments to the lowest effective dose. 1, 2
• Topical 0.1 % capsaicin cream can be used prophylactically to prevent recurrent episodes, with close monitoring for adverse effects. 1, 7
• Co‑management with psychology or psychiatry is essential because anxiety and depression are highly prevalent among CH‑S patients. 5
• Integrating evidence‑based psychosocial interventions with pharmacologic therapy improves long‑term cessation success. 8, 5

Diagnostic Confirmation

• Diagnosis requires stereotypical episodic vomiting that mimics cyclic vomiting syndrome. 1, 3
• At least three vomiting episodes per year must be documented. 8
• A history of compulsive hot bathing or showering for symptom relief is present in roughly 71 % of cases. 1
• Cannabis use pattern supporting the diagnosis includes:
  
  • Use duration longer than one year before symptom onset. 1, 6
  • Average consumption of more than four times per week. 8
  • Daily use, reported in about 68 % of patients. 3
• Before attributing symptoms to CH‑S, clinicians must exclude life‑threatening conditions such as acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction. 1, 2

Common Clinical Pitfalls

• Many patients remain uncertain about the role of cannabis in their illness, often attributing symptoms to food, alcohol, or stress. 8, 5
• Recidivism rates exceed 40 % in several series, underscoring the need for persistent counseling and follow‑up. 8

Emerging Evidence

• Preliminary data suggest that fatty‑acid amide hydrolase inhibitors and cannabidiol may reduce cannabis use in individuals with cannabinoid use disorder, though larger trials are required. 8, 9

Evidence‑Based Facts on Cannabinoid Hyperemesis Syndrome

Diagnostic Criteria

• Patients with CHS typically have a cannabis use history of more than one year, consume more than four times per week, and daily use is reported in roughly two‑thirds of cases. 10

Exclusion of Alternative Diagnoses

• Before confirming CHS, clinicians must rule out life‑threatening conditions such as acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction; this is especially important in the usual age group of adolescents and young adults (approximately 16–34 years) who present repeatedly with vomiting. 10

Epidemiology & Recidivism

• Recidivism exceeds 40 % in reported series, highlighting the need for ongoing counseling and structured follow‑up.
• The frequency of CHS‑related emergency department visits in North America doubled between 2017 and 2021, a trend attributed to higher cannabis potency and broader legalization. [10][11]

Patient Perception & Education

• Many individuals believe cannabis relieves their symptoms while it is actually the cause, creating a paradox that hinders cessation; direct education about this contradictory mechanism is essential at every clinical encounter. [10][12]

CPK Elevation Is Not a Direct Manifestation of Cannabis Hyperemesis Syndrome

Pathophysiology

• Cannabis hyperemesis syndrome (CHS) does not directly cause creatine phosphokinase (CPK) elevation; its core mechanism involves CB1‑receptor activation in the dorsal vagal complex and gastrointestinal tract, leading to cyclic vomiting, nausea, and abdominal pain without primary muscle injury. 13

AGA Guideline Recommendations for Cannabinoid Hyperemesis Syndrome

Diagnostic Framework

• The American Gastroenterological Association (AGA) 2024 guideline establishes a diagnostic framework for cannabinoid hyperemesis syndrome but does not provide specific antiemetic recommendations. 14, 15

Antiemetic Recommendations

• The AGA guideline advises that ondansetron and metoclopramide should not be used as primary antiemetic therapy for CHS because they are ineffective; instead, CB1‑receptor‑targeted or dopamine‑antagonist agents are recommended for acute symptom control. 14

Guideline Recommendations for Proton Pump Inhibitor Use in Cannabinoid Hyperemesis Syndrome

1. Indications / Contra‑indications for PPIs in CHS

• PPIs are not indicated for either acute symptom control or long‑term prophylaxis of cannabinoid hyperemesis syndrome because the disorder is not mediated by gastric acid secretion. American Gastroenterological Association (AGA) 2024 guideline recommends against PPI use in CHS. 16
• PPIs should be prescribed only when a patient has documented upper‑GI bleeding risk factors (e.g., concurrent NSAID use, anticoagulation therapy, or a history of ulcer bleeding). This aligns with standard gastro‑enterology practice. 17
• Repeated vomiting alone does not constitute an indication for PPI therapy unless endoscopic or clinical evidence shows erosive esophagitis, active bleeding, or other acid‑related complications. 17
• The only scenario where a PPI may be appropriate in a CHS patient is the development of documented erosive esophagitis from vomiting or the presence of independent upper‑GI bleeding risk factors (e.g., NSAID use, anticoagulation, prior ulcer bleeding). 17

2. Assessment Prior to Initiating PPI Therapy

• Before prescribing a PPI, clinicians should systematically assess upper‑GI bleeding risk using an evidence‑based strategy that includes: prior bleeding episodes, use of multiple antithrombotic agents, NSAID use combined with age > 60 years, severe comorbidities, or concurrent corticosteroid therapy. 17
• If no bleeding risk factors are identified, PPI therapy should not be started, as it does not prevent CHS episodes or reduce vomiting frequency. [16][17]

3. Acute Management of CHS (Non‑PPI Strategies)

• Cannabis cessation counseling is the cornerstone of acute treatment. 16
• Topical 0.1 % capsaicin cream applied to the abdomen activates TRPV1 receptors and provides rapid relief of nausea and vomiting in CHS. 16
• Haloperidol (or droperidol) is the preferred first‑line dopamine antagonist antiemetic; the AGA guideline advises that ondansetron and metoclopramide should not be used as primary therapy. 16
• Opioids must be avoided because they exacerbate nausea and carry a high addiction risk in this population. 16
• Benzodiazepines (e.g., lorazepam) may be employed for acute symptom control but are not first‑line agents. 16

4. Long‑Term Management of CHS

• Complete cannabis cessation for ≥ 6 months is the definitive cure; symptoms typically resolve after this period or after a duration equivalent to three typical vomiting cycles. 16
• Amitriptyline (starting at a low dose and titrated weekly to a target of 75–100 mg at bedtime) is the mainstay of long‑term pharmacotherapy for CHS. 16
• Structured cannabis‑cessation counseling should be reinforced at every clinical encounter; reported recidivism rates exceed 40 % in series. 16
• Co‑management with psychology or psychiatry is essential because anxiety and depression are highly prevalent among CHS patients and contribute to ongoing cannabis use. 16

5. Risks of Unnecessary PPI Use in CHS

• Misattributing CHS symptoms to reflux or peptic disease leads to unnecessary PPI prescriptions, which provide no benefit and expose patients to potential harms. This misconception is documented in both the 2024 AGA guideline and earlier gastroenterology literature. [16][17]

All bullet points are supported by the cited references and reflect the current AGA guideline recommendations.